Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s stock price rose 3.8% during mid-day trading on Wednesday . The company traded as high as $45.16 and last traded at $45.7990. Approximately 176,374 shares were traded during trading, a decline of 79% from the average daily volume of 844,049 shares. The stock had previously closed at $44.12.

Analyst Ratings Changes

Several research analysts recently commented on XENE shares. Wells Fargo & Company raised their price target on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Thursday, December 11th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. Needham & Company LLC restated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Royal Bank Of Canada raised their price objective on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $54.64.

Xenon Pharmaceuticals Stock Up 1.6%

The firm has a market capitalization of $3.46 billion, a PE ratio of -11.52 and a beta of 0.97. The firm’s 50 day moving average price is $42.59 and its two-hundred day moving average price is $38.21.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.01. During the same quarter in the previous year, the company posted ($0.81) EPS. The company’s revenue was up .0% compared to the same quarter last year. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Ian Mortimer sold 10,830 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $45.73, for a total value of $495,255.90. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $274,380. The trade was a 64.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 25,302 shares of company stock worth $1,146,928 over the last 90 days. 4.07% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vident Advisory LLC boosted its stake in shares of Xenon Pharmaceuticals by 21.4% during the 1st quarter. Vident Advisory LLC now owns 6,574 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 1,161 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Xenon Pharmaceuticals by 27.1% in the first quarter. Alyeska Investment Group L.P. now owns 367,233 shares of the biopharmaceutical company’s stock worth $12,321,000 after buying an additional 78,390 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Xenon Pharmaceuticals by 9.4% in the first quarter. Advisors Asset Management Inc. now owns 14,281 shares of the biopharmaceutical company’s stock valued at $479,000 after acquiring an additional 1,233 shares in the last quarter. Granahan Investment Management LLC boosted its stake in Xenon Pharmaceuticals by 0.8% during the 1st quarter. Granahan Investment Management LLC now owns 183,808 shares of the biopharmaceutical company’s stock valued at $6,167,000 after acquiring an additional 1,475 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after acquiring an additional 32,486 shares in the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.